Anti-PD-L1 Nanobody (VHH), Recombinant, Purified

Anti-PD-L1 Nanobody (VHH), Recombinant, Purified

Catalog #: EG-NB-PDL101
$425.00
View Cart
3D Structure — Nanobody–Epitope Complex
Loading 3D structure…
anti-PD-L1 nanobody complex
PDB 7CZD
nanobody (VHH)   antigen   epitope (53)
Drag to rotate · scroll to zoom

Interactive model of the VHH bound to its structural epitope on PD-L1 (from experimental complex PDB 7CZD). Nanobody in blue, epitope contact residues in red. For research visualization.

Product Description
Product NameAnti-PD-L1 Nanobody (VHH), Recombinant, Purified
DescriptionA purified, engineered VHH nanobody against human PD-L1 for immuno-oncology research. Compact and stable for tissue penetration and multiplexed imaging.
Target / SpecificityHuman PD-L1 (CD274 / B7-H1)
SequenceThis nanobody is an engineered variant based on PDB 7CZD, with higher affinity and stability than the original published sequence.
FormatPurified recombinant single-domain antibody (VHH / nanobody), carrier-free
Tag & ExpressionC-terminal 6×His tag; secreted from HEK293 cells and purified by one-step IMAC from the culture medium.
Molecular Weight~14 kDa (single VHH domain + His6; ~1/10 the size of a conventional IgG)
Purity>90% by SDS-PAGE
Quantity100 µg
FormulationPBS with 50% glycerol (carrier-free); 0.02% sodium azide
ApplicationsIF, flow cytometry, ELISA, checkpoint-ligand detection, immuno-oncology research
Structural EpitopeEpitope mapped from the experimental VHH–antigen complex (PDB 7CZD); 53 antigen contact residues within 5 Å. An interactive 3D complex model is shown on this page.
StorageStore at -20°C; avoid repeated freeze-thaw. Stable 1 year.
AdvantagesNanobodies are the smallest functional antibody fragments: exceptional thermal and chemical stability, single-domain, high-yield recombinant production, and access to cryptic epitopes and dense tissue that conventional antibodies cannot reach.
Product Documents
DatasheetEG-NB-PDL101 Product Datasheet
Download PDF
Related Products